Compare Quest Diagnostics Inc (DGX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Twilio Inc — how do they compare? Quest Diagnostics Inc trades at $236.29 (market cap $26.24B), while Twilio Inc trades at $248 (market cap $37.87B). The key difference: Twilio Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| DGX | TWLO | |
|---|---|---|
Market Cap | $26.24B | $37.87B |
Sector | Health | Technology |
52-Week High | $238.50 | $255.95 |
52-Week Low | $173.49 | $100.09 |
Enterprise Value | $32.00B | $36.28B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $236.04, down 0.61% on the day, as the stock consolidates near recent highs following strong Q2 2026 earnings. The company has delivered three consecutive quarterly earnings beats, with Q2 EPS of $3.12 exceeding expectations by 10.6%. Revenue growth accelerated to 10.2% year-over-year, supported by strong testing demand and strategic partnerships. Technical indicators show a bullish trend with the stock trading near pivot point resistance at $238.
The outlook remains positive with raised 2026 guidance and consistent dividend payments, though valuation multiples appear full at 25.2x P/E. Key risks include margin pressure from lower-margin contracts and rising project costs. Analyst consensus leans bullish with a $249.50 price target representing 5.7% upside potential from current levels.
Twilio (TWLO) trades at $249.42, down 2.55% on the day but near its 52-week high after a strong rally. The stock shows bullish technical signals with moving averages supporting upward momentum, while RSI levels indicate potential overbought conditions. Fundamentally, revenue growth accelerated to 22% year-over-year in Q2 2026, with net income turning positive in 2025 after years of losses. Recent earnings beats and raised full-year guidance to 18-18.5% revenue growth have fueled investor optimism.
Outlook remains positive with Wall Street consensus at Buy (76.93% of analysts) and a $266.31 price target, implying ~7% upside. Key opportunities include sustained free cash flow generation and AI-driven growth, though risks involve high valuation multiples (P/E 34.06) and insider selling activity. Execution on guidance and competitive pressures in cloud communications will be critical for continued outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
